Core deficits are identified in 2 domains: social communication/interaction and restrictive, repetitive patterns of behavior. Dr Hyman got no personal reimbursement from the company the funding was for staff time for recruitment and assessment and clinical research center support for the trial.Īutism spectrum disorder (ASD) is a common neurodevelopmental disorder with reported prevalence in the United States of 1 in 59 children (approximately 1.7%). Funding was for the staff to complete the assessments required for the clinical trial. University of Rochester will be leaving the trial in 2019 (withdrawal submitted) because of staffing, and that reimbursement for staff time does not cover the cost of participation. The University of Rochester (Dr Hyman’s institution) was 1 of >40 sites and had 2 study participants in 2018. Dr Hyman is the site principal investigator of a clinical trial of a novel agent being tested to promote social function in patients with autism. Her years of relationship with the company are 2015 to the present. Once it is studied and marketed (if appropriate), Dr Levy will (possibly in the future) earn some money. This application is the focus of a National Institutes of Health R21 grant, for which Dr Levy is funded for ∼2% of her salary.
Dr Levy has not received any money yet from this company. This application is being developed to assist in nutritional and dietary management of children with autism.
Dr Levy is on the advisory board for the application’s development. POTENTIAL CONFLICT OF INTEREST: MeMix LLC is a company that makes an application (for phones).
0 kommentar(er)
